Antibody titers and protection against a SARS-CoV-2 infection

Dimeglio, Chloé; Hérin, Fabrice; Martin‐Blondel, Guillaume; Miédougé, Marcel; Izopet, Jacques

doi:10.1016/j.jinf.2021.09.013

Cited by 108 publications

(125 citation statements)

References 8 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…According to data provided by Dimeglio et al [11], sufficient protection of 89% can be obtained with a neutralizing antibody level of 141 BAU/mL, which is approximately ten times the level considered in this study as the limit for positive results. In our study, only 64% of vaccinated people with no history of COVID-19 exceeded this anti-S antibody level, in contrast to 90% of those with a history of the disease.…”

Section: Discussionmentioning

confidence: 52%

Effect of COVID-19 on Anti-S Antibody Response in Healthcare Workers Six Months Post-Vaccination

et al. 2021

View full text Add to dashboard Cite

The current study aimed to determine to what extent prior COVID-19 infection affects the response of specific antibodies following vaccination. The study involved 173 healthcare professionals who completed the two-dose vaccination course with BNT162b2, including 40 who previously experienced clinical COVID-19. The levels of anti-SARS-CoV-2 S1S2 IgG (anti-S) and, in some cases, anti-SARS-CoV-S-RBD IgG (anti-S-RBD) were determined six months after complete vaccination. A level exceeding the cut-off values for both anti-S and anti-S-RBD was observed in 100% of subjects, but after setting the analysis to 5- and 10-fold cut-off levels, the percentage of subjects meeting this criterion was significantly higher for anti-S-RBD. The 100-fold cut-off level was achieved by only 21% and 16% for anti-S and anti-S-RBD, respectively. Anti-S and anti-S-RBD levels above ten times the positive cut-off were respectively observed in 91% and 100% individuals with a history of COVID-19, while among those without COVID-19, these values were 64% and 90%, respectively. Significantly higher incidence of values above 10 and 100 times the cut-off became apparent among people with a history of COVID-19. In conclusion, vaccination against COVID-19 following infection with the disease provides higher levels of specific antibodies 6 months after vaccination than those of individuals without a history of the disease, which supports the use of a booster dose, particularly for those who have not experienced SARS-CoV-2 infection.

show abstract

Section: Discussionmentioning

confidence: 52%

Effect of COVID-19 on Anti-S Antibody Response in Healthcare Workers Six Months Post-Vaccination

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This case series study was conducted from July 1, 2021, to August 5, 2021. A fourth dose of the messenger RNA-based BNT162b2 vaccine (Pfizer-BioNTech) was given to the 37 solid organ transplant recipients, including 5 (13.5%) who had a weak response to the previous 3 doses (antibody concentration <14 binding antibody units [BAU]/mL) 4 and 31 (83.8%) who had no response to the 3 previous doses. All participants provided oral informed consent and received approval of the medical staff ( Table ).…”

Section: Methodsmentioning

confidence: 99%

Assessment of 4 Doses of SARS-CoV-2 Messenger RNA–Based Vaccine in Recipients of a Solid Organ Transplant

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…We read with interest the article by Dimeglio et al 1 , showing the importance of the SARS-CoV-2 anti-S antibody response. Along with previous results showing a strong decrease of antibody and neutralization titers after vaccination 2,3 , especially for Gamma variant, their results highlight the usefulness of assessing antibody levels among HealthCare Workers (HCWs) and to monitor the effects of emerging SARS-CoV-2 variants.…”

Section: Dear Editormentioning

confidence: 99%

Alpha (B.1.1.7) and Delta (B.1.617.2 – AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage

Lebourgeois

Menidjel

Chenane

et al. 2022

Journal of Infection

View full text Add to dashboard Cite

Antibody titers and protection against a SARS-CoV-2 infection

Cited by 108 publications

References 8 publications

Effect of COVID-19 on Anti-S Antibody Response in Healthcare Workers Six Months Post-Vaccination

Effect of COVID-19 on Anti-S Antibody Response in Healthcare Workers Six Months Post-Vaccination

Assessment of 4 Doses of SARS-CoV-2 Messenger RNA–Based Vaccine in Recipients of a Solid Organ Transplant

Alpha (B.1.1.7) and Delta (B.1.617.2 – AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage

Contact Info

Product

Resources

About